Inhibrx Biosciences, Inc. (INBX)

NASDAQ · Pharmaceuticals & Biotech · Biological Products, (No Diagnostic Substances)

Price
$100.33
Day
-9.34%
Market cap
$1.48B

Close 2026-09-23.

The company

Overview We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential. Our Strategy Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions. We are a biopharmaceutical company aiming to develop a differentiated and sustainable product portfolio by focusing on the following: Rapidly advance and optimize the clinical development of our lead programs. Since entering the clinic, we have made great strides in our clinical programs, with the successful completion of two registration-enabling trials.

From Item 1: Overview · Our Strategy.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings